Table 4. Univariate and multivariate analysis of overall survival and progression-free survival in GUH cohort.
|
Overall survival |
Progression-free survival |
|||||
|---|---|---|---|---|---|---|
| |
Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
||
| Variables | 5-Year survival rate (%) | HR P-value | HR (95% CI) P-value | 5-Year survival rate (%) | HR P-value | HR (95% CI) P-value |
| Age |
|
0.605 |
|
|
0.743 |
|
| ⩽65 years | 76 | 0.359–0.992 | 65 | 0.473–1.167 | ||
| >65 years |
66 |
0.055 |
|
57 |
0.197 |
|
| Sex |
|
1.343 |
|
|
1.128 |
|
| Male | 67 | 0.835–2.158 | 0.922 (0.633–1.316) | 59 | 0.732–1.737 | 1.130 (0.807–1.553) |
| Female |
76 |
0.264 |
0.665 |
60 |
0.585 |
0.468 |
| Smoking |
|
1.606 |
|
|
1.544 |
|
| Yes | 65 | 0.998–2.584 | 0.895 (0.610–1.328) | 55 | 0.999–2.384 | 1.242 (0.871–1.751) |
| No |
76 |
0.062 |
0.578 |
67 |
0.051 |
0.227 |
| p-Stage |
|
5.981 |
|
|
13.26 |
|
| I or II | 78 | 3.213–11.13 | 3.401 (2.059–5.569) | 72 | 7.147–24.62 | 2.175 (1.730–2.725) |
| III or IV |
38 |
<0.001 |
<0.001 |
16 |
<0.001 |
<0.001 |
| Histology |
|
1.366 |
|
|
1.252 |
|
| AC | 71 | 0.809–2.306 | 1.029 (0.557–1.901) | 61 | 0.780–2.009 | 0.950 (0.721–1.252) |
| Non-AC |
66 |
0.323 |
0.926 |
57 |
0.351 |
0.715 |
| Lymphatic permeation |
|
3.232 |
|
|
3.574 |
|
| Positive | 52 | 1.985–5.264 | 39 | 2.280–5.602 | ||
| Negative |
83 |
<0.001 |
|
74 |
<0.001 |
|
| Vascular invasion |
|
3.624 |
|
|
3.748 |
|
| Positive | 50 | 2.170–6.051 | 37 | 2.335–6.018 | ||
| Negative |
80 |
<0.001 |
|
72 |
<0.001 |
|
| ASCT2 |
|
1.657 |
|
|
1.551 |
|
| High | 61 | 1.035–2.654 | 1.179 (0.911–1.534) | 41 | 1.008–2.388 | 1.093 (0.868–1.382) |
| Low |
77 |
0.035 |
0.209 |
54 |
0.046 |
0.447 |
| CD98 |
|
1.541 |
|
|
1.710 |
|
| High | 63 | 0.925–2.569 | 48 | 1.073–2.724 | ||
| Low |
73 |
0.137 |
|
65 |
0.024 |
|
| Ki-67 |
|
1.748 |
|
|
1.686 |
|
| High | 61 | 1.083–2.823 | 49 | 1.091–2.607 | ||
| Low |
76 |
0.031 |
|
68 |
0.018 |
|
| CD34 |
|
1.876 |
|
|
1.642 |
|
| High | 62 | 1.170–3.010 | 51 | 1.067–2.526 | ||
| Low |
77 |
0.012 |
|
68 |
0.024 |
|
| p-mTOR |
|
1.475 |
|
|
2.088 |
|
| High | 61 | 0.868–2.505 | 42 | 1.269–3.437 | ||
| Low | 73 | 0.130 | 66 | 0.004 | ||
Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.
Bold entries show statistically significant difference.